ES2202156T3 - Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f. - Google Patents

Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f.

Info

Publication number
ES2202156T3
ES2202156T3 ES00950904T ES00950904T ES2202156T3 ES 2202156 T3 ES2202156 T3 ES 2202156T3 ES 00950904 T ES00950904 T ES 00950904T ES 00950904 T ES00950904 T ES 00950904T ES 2202156 T3 ES2202156 T3 ES 2202156T3
Authority
ES
Spain
Prior art keywords
compounds
descarboxi
prostaglandina
phosphinic
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00950904T
Other languages
English (en)
Inventor
Mitchell Anthony Delong
John August Wos
Biswanath De
Frank Hallock Ebetino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Application granted granted Critical
Publication of ES2202156T3 publication Critical patent/ES2202156T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/303—Cycloaliphatic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Compuesto que tiene la siguiente estructura **fórmula** caracterizado porque, R1 es H o una cadena de alquilo que está constituida por 1 a 4 átomos de carbono, R2 es H, alquilo, heteroalquilo, anillo alifático carbocíclico, anillo alifático heterocíclico, anillo aromático o anillo heteroaromático; X es O ó S; Y es O, S ó NH. V es alquilo C4 o heteroalquilo M4; a es un enlace sencillo, doble enlace en cis o doble enlace en trans; b es un enlace sencillo, doble enlace en trans o triple enlace; cuando a es un enlace sencillo, W es OH ó N(R3)(OR4); caracterizado porque R3 se selecciona de entre H, una cadena de alquilo que está constituida por 1 a 4 átomos de carbono o una cadena de heteroalquilo constituida por 1 a 4 átomos de carbono.
ES00950904T 1999-08-04 2000-08-01 Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f. Expired - Lifetime ES2202156T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14713299P 1999-08-04 1999-08-04

Publications (1)

Publication Number Publication Date
ES2202156T3 true ES2202156T3 (es) 2004-04-01

Family

ID=22520396

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00950904T Expired - Lifetime ES2202156T3 (es) 1999-08-04 2000-08-01 Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f.

Country Status (12)

Country Link
US (1) US6372730B1 (es)
EP (1) EP1202999B1 (es)
JP (1) JP4846150B2 (es)
AT (1) ATE243215T1 (es)
AU (1) AU776375B2 (es)
CA (1) CA2380326C (es)
CO (1) CO5180630A1 (es)
DE (1) DE60003435T2 (es)
ES (1) ES2202156T3 (es)
IL (1) IL147771A0 (es)
NO (1) NO20020523L (es)
WO (1) WO2001010873A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
US6884858B2 (en) 1999-10-19 2005-04-26 Texas Petrochemicals Lp Process for preparing polyolefin products
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
WO2006047466A2 (en) * 2004-10-21 2006-05-04 Duke University Ophthamological drugs
EP1985309B1 (en) 2005-12-26 2016-11-23 LTT Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
WO2008139804A1 (ja) * 2007-05-14 2008-11-20 Ltt Bio-Pharma Co., Ltd. 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
EP2361918A1 (en) * 2008-11-18 2011-08-31 LTT Bio-Pharma Co., Ltd. Novel prostaglandin e1 derivative, and nanoparticle having same encapsulated therein
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CN105319283A (zh) * 2014-07-17 2016-02-10 上海市农药研究所 检测三联吡啶含量的方法
JP7901059B2 (ja) * 2022-10-26 2026-08-05 信越化学工業株式会社 共役二重結合を有する有機ハロゲン化合物、そのアセテート化合物及びアルコール化合物の製造方法、並びに該有機ハロゲン化合物を合成する為に使用される化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US5312832A (en) 1991-05-17 1994-05-17 Allergan, Inc. Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5658897A (en) * 1996-04-08 1997-08-19 Allergan Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
KR20010023837A (ko) * 1997-09-09 2001-03-26 데이비드 엠 모이어 Ｆｐ 작동약으로 유용한 방향족 ｃ16-ｃ20-치환된테트라히드로 프로스타글란딘
ID24845A (id) * 1997-09-09 2000-08-24 Procter & Gamble Prostaglandin tetrahidro tersubstitusi c16-c20 aromatik yang berguna sebagai agonis fp
CA2303764C (en) * 1997-09-09 2005-02-15 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease

Also Published As

Publication number Publication date
CO5180630A1 (es) 2002-07-30
AU6393300A (en) 2001-03-05
CA2380326A1 (en) 2001-02-15
DE60003435T2 (de) 2004-05-19
NO20020523D0 (no) 2002-02-01
EP1202999A1 (en) 2002-05-08
EP1202999B1 (en) 2003-06-18
CA2380326C (en) 2008-03-18
AU776375B2 (en) 2004-09-09
IL147771A0 (en) 2002-08-14
NO20020523L (no) 2002-04-02
WO2001010873A1 (en) 2001-02-15
JP4846150B2 (ja) 2011-12-28
ATE243215T1 (de) 2003-07-15
JP2003506454A (ja) 2003-02-18
DE60003435D1 (de) 2003-07-24
US6372730B1 (en) 2002-04-16

Similar Documents

Publication Publication Date Title
CA2303764A1 (en) Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
CA2303801A1 (en) Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
CO5180630A1 (es) Nuevos analogos de 2-decarboxi-2-fosfinico prostaglandina f.
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
CA2364944A1 (en) C16 unsaturated fp-selective prostaglandins analogs
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
BR0008776A (pt) Análogos de prostaglandinas fp-seletivosinsaturados c16
BR0008716A (pt) Inibidores de metaloprotease contendo alquenil ou alquinil
CA2324343A1 (en) C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
CA2324590A1 (en) C11 oxymyl and hydroxylamino prostaglandins useful as fp agonists
IL166103A0 (en) Pyrrolidine derivatives and their use
WO2001070693A3 (en) Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
AU3342899A (en) Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
CO5271694A1 (es) Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion
DE69527854D1 (de) Derivate substituierter amidinonaphthylester
DE60005525D1 (de) 2-aminotetraline zur behandlung von glaukom